Who is sponsoring NCT04504123?

NCT04504123 is sponsored by University of Iowa.

What drugs are being tested in NCT04504123?

Interventions in NCT04504123: Doxycycline Hyclate, Placebo.

What condition does NCT04504123 study?

NCT04504123 studies Exudative Macular Degeneration, Wet Age-related Macular Degeneration.

Is NCT04504123 still recruiting?

NCT04504123 is currently recruiting now. Last updated 2 April 2026.

Last reviewed 2026-04-02 · How we verify

NCT04504123

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MMP-9 Inhibition for Recalcitrant Wet AMD

Recruiting now Phase 2 Last updated 2 April 2026

What this trial tests

Phase 2 trial testing Doxycycline Hyclate in Exudative Macular Degeneration in 50 participants. Currently enrolling.

Timeline

4 November 2020

Primary endpoint
31 December 2026

1 March 2027

Quick facts

Lead sponsor	University of Iowa
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	50
Start date	4 November 2020
Primary completion	31 December 2026
Estimated completion	1 March 2027
Sites	1 location across United States

Drugs / interventions tested

Doxycycline Hyclate — full drug profile →
Placebo

Conditions studied

Exudative Macular Degeneration — all drugs for Exudative Macular Degeneration →
Wet Age-related Macular Degeneration — all drugs for Wet Age-related Macular Degeneration →

Sponsor

University of Iowa

Who can join

Adults 50 to 99, any sex, with Exudative Macular Degeneration or Wet Age-related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Wet (or neovascular) form of age-related macular degeneration (wAMD) is the most common cause of blindness in the Western world. Currently, anti-vascular endothelial growth factor (VEGF) intravitreal injections (IVI) remain the standard-of-care treatment for wAMD. Previous studies show that about 90% of treated patients lose minimal visual function after 2 years of follow-up. There is still, a subset of 15% patients, incomplete responders, that do not improve and possibly worsen due to the persistence of sub-retinal fluid (with or without intra-retinal fluid) with chronic treatment. The investigators plan to evaluate the effect of oral doxycycline versus placebo on the anatomic and functional outcomes in persistent sub-retinal eye fluid in neovascular wet age-related macular degeneration. This subset are incomplete or non-responders to current anti-VEGF intravitreal therapy.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Approaches for Increasing Cerebral Efflux of Amyloid-β in Experimental Systems.
Loeffler DA. · · 2024 · cited 8× · PMID 38875041 · DOI 10.3233/jad-240212
Epigenetic drivers of metalloproteinases and metastasis.
Seehawer M, Polyak K. · · 2025 · cited 1× · PMID 40089451 · DOI 10.1016/j.tcb.2025.02.010

Verify or expand the search:

Other trials of Doxycycline Hyclate

Trials testing the same drug.

NCT04762134 — Doxycycline Intervention for Bacterial STI ChemoprOphylaxis (DISCO) · NA · recruiting
NCT04582383 — Comparative Effectiveness Study of Spironolactone Versus Doxycycline for Acne · Phase 4 · active not recruiting
NCT05112211 — Multi-model Image of Doxycycline in TAO · NA · recruiting
NCT05399290 — Subantimicrobial Doxycycline in Acne · Phase 4 · completed
NCT03508232 — Doxycycline to Protect Heart Muscle After Heart Attacks · Phase 2 · completed

Other recruiting trials for Exudative Macular Degeneration

Currently open trials in the same condition.

NCT05093374 — Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting · Phase 4 · recruiting

Other University of Iowa trials

Trials by the same sponsor.

NCT07224269 — Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis · EARLY_PHASE1 · not yet recruiting
NCT07244809 — Probing the Role of Mitochondrial Oxidative Stress in Impaired Vascular Function Among Young Adults With Early Life Adve · NA · recruiting
NCT07097961 — Paediatric Post-TB Pulmonary Rehab Study · NA · recruiting
NCT06951594 — Robotic-Assisted Versus Manual Electrode Array Insertion · NA · recruiting
NCT06710119 — Effect of Custom Dynamic Orthoses on Forefoot Loading · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04504123 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Iowa
Last refreshed: 2 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04504123.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing